IASLC 2026 World Conference on Lung Cancer
SEPTEMBER 12 – 15, 2026 | SEOUL, REPUBLIC OF KOREA

Efficacy and Safety of GFH375 in Advanced Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

Ziming Li, MD, PhD

Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine--Shanghai, China

, Ziming Li, Xinghao Ai, Peng Chen, Wenxiu Yao, Hong Zong, Lin Wu, Tongmei Zhang, Jianbo He, Qitao Yu, Zuoxing Niu, Yuping Sun, Jian Fang, Jianxin Xue, Anna Li, Kejing Tang, Lingjun Zhu, Zhengbo Song, Ying Yuan, Meili Sun, Lin Zhao, Yingying Du, Yu Wang, Haige Shen, Huaqiang Zhu, Chanli Zheng, Shuang Wang, Zhao Cui

NSCLC at 600 mg (n=75)


NSCLC at 600 mg
(n=71)*
100
50
-50
-100
Prior lines of therapy


600mg QD (N=75)
Event, n(%) 40 (53.3)
Censor, n(%) 35 (46.7)
0.75
0.50
0.25
0.00
Number at risk



Adverse events, n(%)	600 mg QD (N=75)

Adverse events, n(%)	ICIs 28~90 days* (n=48)	ICIs >90 days (n=27)


KRAS status
Undetectable
Detectable
N
Median PFS (95% CI), months
KRAS^G12D
KRAS^G12D
1.00
0.75
0.50
0.25
0.00
PFS probability
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Follow up time (months)
Undetectable 30 29 24 22 21 20 19 16 16 10 8 7 5 5
Detectable 43 43 37 32 30 27 18 13 13 11 8 8 5 4
Nonaltered
Altered
1 0

52.1% confirmed ORR

8.3 months of median PFS

Median OS not reached

9.6 months among taxane-naïve patients

Thank You